4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Zhengye Biotechnology Holding Limited (ZYBT) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Jilin, China with about 269 employees. Its market capitalization is roughly $37 million. In the fiscal year ended 2025-12-31, ZYBT reported $116M in revenue and ($70M) in net income.
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China.
Interactive charts & full statements → Open the ZYBT valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $116M | $186M | $212M | $260M | — |
| Gross Profit | $24M | $91M | $118M | $148M | — |
| Operating Income (EBIT) | ($68M) | $17M | $48M | $66M | — |
| Net Income | ($70M) | $11M | $32M | $47M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | $0M | ($16M) | ($40M) | ($21M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $436M | $493M | $500M | $520M | — |
| Total Liabilities | $130M | $141M | $161M | $163M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZYBT viewer.
About TickerBase · Data methodology & sources